Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{3-[5-(1H‑1,2,4‑triazol‑3‑yl)‑1H‑indazol‑3‑yl]phenyl}furan‑2-carboxamide is an experimental small molecule compound containing fused indazole and triazole heterocycles linked to a phenylene and furan carboxamide moiety. It has been catalogued in chemical and drug databases (DrugBank DB07020; ChEMBL1230051; ZINC000020149009), but there are no published data on its clinical use or mechanism of action. The structure suggests potential for biological activity due to the presence of pharmacologically relevant indazole and triazole rings[1][6][8]. No approved indications or clinical trials are reported for this compound[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide.